Congenital heart disease is a leading cause of death in the newborn period, and man-made grafts currently used for reconstruction are associated with multiple complications. Tissue engineering can provide an alternative source of vascular tissue in congenital cardiac surgery. Clinical trials have been successful overall, but the most frequent complication is graft stenosis. Recent studies in animal models have indicated the important role of the recipient׳s immune response in neotissue formation, and that modulating the immune response can reduce the incidence of stenosis.
Keywords: Bone marrow-derived mononuclear cells; Congenital cardiac disease; Fontan; Surgery; Tissue engineering; Tissue-engineered vascular graft.
Copyright © 2017 Elsevier Inc. All rights reserved.